Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AXSM 
Axsome Therapeutics Inc (AXSM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: AXSM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $177.9
1 Year Target Price $177.9
| 14 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.96% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.38B USD | Price to earnings Ratio - | 1Y Target Price 177.9 |
Price to earnings Ratio - | 1Y Target Price 177.9 | ||
Volume (30-day avg) 19 | Beta 0.51 | 52 Weeks Range 75.56 - 139.13 | Updated Date 10/18/2025 |
52 Weeks Range 75.56 - 139.13 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -49.88% | Operating Margin (TTM) -29.87% |
Management Effectiveness
Return on Assets (TTM) -21.9% | Return on Equity (TTM) -280.69% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 5899475350 | Price to Sales(TTM) 12.9 |
Enterprise Value 5899475350 | Price to Sales(TTM) 12.9 | ||
Enterprise Value to Revenue 11.92 | Enterprise Value to EBITDA -14.81 | Shares Outstanding 49901487 | Shares Floating 41987111 |
Shares Outstanding 49901487 | Shares Floating 41987111 | ||
Percent Insiders 15.86 | Percent Institutions 77.57 |
Upturn AI SWOT
Axsome Therapeutics Inc
Company Overview
History and Background
Axsome Therapeutics, Inc. was founded in 2012. It is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders with significant unmet needs. Initially focused on depression, the company has expanded its pipeline to include treatments for other CNS conditions like narcolepsy and Alzheimer's disease agitation.
Core Business Areas
- CNS Therapeutics Development: Focuses on developing and commercializing novel therapies for central nervous system (CNS) disorders. Primary focus is on treatments for major depressive disorder (MDD), Alzheimer's disease agitation, and narcolepsy.
Leadership and Structure
The company is led by Herriot Tabuteau, MD, as CEO. The organizational structure consists of various departments including research & development, clinical operations, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- AUVELITY (dextromethorphan HBr and bupropion HCl): A novel oral NMDA receptor antagonist with multimodal activity. Approved for the treatment of Major Depressive Disorder (MDD). Competitors include traditional SSRIs and SNRIs, as well as other atypical antidepressants. Market share is growing as AUVELITY establishes itself as a treatment option.
- SUNOSI (solriamfetol): A dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA). The competitors are Wakix and Xyrem/Xywav. Axsome purchased SUNOSI from Jazz Pharmaceuticals in 2022. Exact sales numbers under Axsome have not been disclosed but will come out with future reports.
- AXS-05 (dextromethorphan/quinidine): Is the same formulation as Auvelity. It is being considered for other indications such as Alzheimer's Disease Agitation. Currently this drug is awaiting approval by the FDA.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically CNS therapeutics, is characterized by high regulatory hurdles, lengthy development timelines, and significant investment in research and development. The need is very high, especially with respect to geriatric patients.
Positioning
Axsome Therapeutics is positioned as an innovative company focused on developing novel treatments for underserved CNS disorders. Its competitive advantages include its pipeline of differentiated products and its focus on unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for CNS disorders is substantial, estimated to be billions of dollars annually. Axsome is focusing on specific segments within the broader CNS market, such as depression, narcolepsy, and Alzheimer's disease agitation. They are well-positioned to obtain substantial marketshare if AXS-05 receives FDA approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Approved products (AUVELITY, SUNOSI)
- Strong pipeline of clinical-stage assets
- Experienced management team
Weaknesses
- Reliance on successful clinical trials and regulatory approvals
- Relatively small commercial infrastructure
- Limited track record of commercial success prior to AUVELITY
Opportunities
- Expanding indications for existing products
- Acquiring or licensing additional assets
- Partnerships with larger pharmaceutical companies
- Addressing unmet needs in CNS disorders
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory setbacks
- Patent challenges
- Pricing pressures
Competitors and Market Share
Key Competitors
- LLY
- VRTX
- JAZZ
Competitive Landscape
Axsome Therapeutics is a smaller company compared to many of its competitors, but it has a differentiated pipeline of innovative therapies. Its success depends on its ability to execute its clinical and commercial strategies effectively.
Major Acquisitions
SUNOSI from Jazz Pharmaceuticals
- Year: 2022
- Acquisition Price (USD millions): 530
- Strategic Rationale: Acquisition of SUNOSI expanded Axsome's commercial portfolio and provided access to a revenue-generating product in the narcolepsy market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in the company's clinical pipeline and the acquisition of SUNOSI.
Future Projections: Future growth is expected to be driven by the commercial success of AUVELITY, the potential approval of other pipeline candidates, and expansion into new markets.
Recent Initiatives: Recent initiatives include the commercial launch of AUVELITY, advancing clinical trials for other pipeline candidates, and exploring potential acquisitions or partnerships.
Summary
Axsome Therapeutics is a biopharmaceutical company with a focus on CNS disorders. It has achieved significant milestones with the approval of AUVELITY and the acquisition of SUNOSI. However, the company faces challenges related to commercial execution, clinical trial success, and competition. It needs to carefully manage its resources and execute its strategies effectively to realize its full potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Press releases, Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axsome Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-11-19 | Founder, Chairman, CEO & President Dr. Herriot Tabuteau M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 846 | Website https://www.axsome.com |
Full time employees 846 | Website https://www.axsome.com | ||
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.